PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results
13 août 2024 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting
08 août 2024 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
07 août 2024 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024
05 août 2024 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
01 août 2024 07h45 HE
|
PDS Biotechnology Corporation
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation...
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
31 juil. 2024 16h01 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference
29 juil. 2024 08h00 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer
12 juin 2024 08h00 HE
|
PDS Biotechnology Corporation
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with...
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
15 mai 2024 08h00 HE
|
PDS Biotechnology Corporation
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global...
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
09 mai 2024 17h46 HE
|
PDS Biotechnology Corporation
30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09,...